Other indications (e.g. myeloproliferative diseases)
Follow-Up Treatment
A Phase 2 Multicenter Study of TL-895 in Subjects with
A Phase 2 Multicenter Study of TL-895 in Subjects with
A Phase-II multicenter study of TL-895 in subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor
Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment
Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis
A Phase 2 Multicenter Study of TL-895 in Subjects with
A Phase 2 Multicenter Study of TL-895 in Subjects with
A Phase-II multicenter study of TL-895 in subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor
Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment
Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis
